Genmab Announces Financial Results for the Nine Months of 2025
6/11 17:03
November 6, 2025 Copenhagen, Denmark; Interim Report for the Nine Months Ended September 30, 2025 Highlights Announcement of Genmab’s proposed acquisition of Merus N.V. (Merus) Genmab revenue increased 21% compared to the first nine months of 2024 , to $2,662 million FDA granted BTD to Rina-S ® in...